Article 1
Open ↗Annexes I and II to Decision 2008/911/EC are amended in accordance with the Annex to this Decision.
Source
2012/67/EU: Commission Implementing Decision of 3 February 2012 amending Decision 2008/911/EC establishing a list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products (notified under document C(2012) 514) Text with EEA relevance
2012/67/EU: Commission Implementing Decision of 3 February 2012 amending Decision 2008/911/EC establishing a list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products (notified under document C(2012) 514) Text with EEA relevance
Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗
Article 2
Open ↗This Decision is addressed to the Member States.
Supplementary provisions
ANNEXSupplementary provisions
Open ↗ANNEX Decision 2008/911/EC is amended as follows: (1) in Annex I, the following substance is inserted after Pimpinella anisum L.: ‘ Thymus vulgaris L., Thymus zygis Loefl. ex L., aetheroleum’; (2) in Annex II, the following is inserted after the entry on Pimpinella anisum L.: ‘ COMMUNITY LIST ENTRY ON THYMUS VULGARIS L., THYMUS ZYGIS LOEFL. EX L., AETHEROLEUM Scientific name of the plant Thymus vulgaris L., Thymus zygis Loefl. ex L. Botanical family Lamiaceae Herbal preparation(s) Essential oil obtained by steam distillation from the fresh flowering aerial parts of Thymus vulgaris L., Thymus zygis Loefl. ex L. or a mixture of both species European Pharmacopoeia monograph reference 01/2008:1374 Indication(s) Traditional herbal medicinal product for the relief of symptoms in coughs and colds. The product is a traditional herbal medicinal product for use in the specified indication exclusively based upon long-standing use. Type of tradition European Specified strength Please see “Specified posology” Specified posology Adults and elderly Cutaneous use: in liquid and semi-solid dosage forms in concentrations up to 10 %; apply up to 3 times daily. Use as bath additive: 0,007-0,025 g per litre. Adolescents Use as bath additive: 0,007-0,025 g per litre Children 6-12 years Use as bath additive: 0,0035-0,017 g per litre Children 3-6 years Use as bath additive: 0,0017-0,0082 g per litre One bath every day or every second day. The cutaneous use in children and adolescents under 18 years of age is not recommended (see section “Special warnings and precaution for use”). The use as bath additive in children under 3 years of age is not recommended (see section “Special warnings and precaution for use”). Route of administration Cutaneous use: apply to the chest and the back. Use as a bath additive: recommended temperature of bath: 35-38 °C. Duration of use or any restrictions on the duration of use Duration of a bath: 10-20 minutes. If the symptoms persist longer than 1 week, a doctor or a qualified health care practitioner should be consulted. Any other information necessary for the safe use Contraindications Hypersensitivity to the active substance. Use as bath additive: Full baths are contraindicated in cases of open wounds, large skin injuries, acute skin diseases, high fever, severe infections, severe circulatory disturbances and cardiac insufficiency. Special warnings and precautions for use Cutaneous use: Like other essential oils Thyme oil should not be applied to the face particularly in the nasal area of babies and infants under the age of 2 years because of the risk of a laryngospasm. When dyspnoea, fever or purulent sputum occurs, a doctor or a qualified health care practitioner should be consulted. The use in children and adolescents under 18 years of age is not recommended due to lack of adequate data. Use as bath additive: When dyspnoea, fever or purulent sputum occurs, a doctor or a qualified health care practitioner should be consulted. The use in children under 3 years of age is not recommended because medical advice should be sought and due to lack of adequate data. In cases of hypertension, a full bath should be used with caution. Interactions with other medicinal products and other forms of interaction None reported. Pregnancy and lactation Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. Effects on ability to drive and use machines No studies on the effect on the ability to drive and use machines have been performed. Undesirable effects Hypersensitivity reactions and skin irritation have been observed. The frequency is not known. If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted. Overdose No case of overdose has been reported. Pharmaceutical particulars [If necessary] Not applicable. Pharmacological effects or efficacy plausible on the basis of long-standing use and experience [If necessary for the safe use of the product] Not applicable.’
Other acts of the same type
Council Decision (EU) 2021/650 of 19 April 2021 on the signing, on behalf of the Union, of the Agreement in the form of an Exchange of Letters between the European Union and the United States of America pursuant to Article XXVIII of the General Agreement on Tariffs and Trade (GATT) 1994 relating to the modification of concessions on all the tariff rate quotas included in the EU Schedule CLXXV as a consequence of the United Kingdom’s withdrawal from the European UnionCouncil Decision (EU) 2021/651 of 19 April 2021 on the signing, on behalf of the Union, of the Agreement in the form of an Exchange of Letters between the European Union and the Argentine Republic pursuant to Article XXVIII of the General Agreement on Tariffs and Trade (GATT) 1994 relating to the modification of concessions on all the tariff-rate quotas included in the EU Schedule CLXXV as a consequence of the United Kingdom’s withdrawal from the European UnionCommission Decision (EU) 2021/660 of 19 April 2021 amending Decision (EU) 2020/491 on relief from import duties and VAT exemption on importation granted for goods needed to combat the effects of the COVID-19 outbreak during 2020 (notified under document C(2021) 2693)Council Implementing Decision (CFSP) 2021/636 of 16 April 2021 implementing Decision 2013/798/CFSP concerning restrictive measures against the Central African RepublicCouncil Decision (CFSP) 2021/613 of 15 April 2021 amending Decision (CFSP) 2016/1693 concerning restrictive measures against ISIL (Da’esh) and Al-Qaeda and persons, groups, undertakings and entities associated with themCommission Implementing Decision (EU) 2021/627 of 15 April 2021 laying down rules on keeping and accessing of the logs in the European Travel Information and Authorisation System (ETIAS) pursuant to Regulation (EU) 2018/1240 of the European Parliament and of the CouncilCommission Implementing Decision (EU) 2021/659 of 15 April 2021 concerning exemptions from the extended anti-dumping duty on certain bicycle parts originating in the People’s Republic of China pursuant to Regulation (EC) No 88/97 (notified under document C(2021) 2416)Commission Implementing Decision (EU) 2021/609 of 14 April 2021 amending Implementing Decision (EU) 2020/439 as regards harmonised standards on packaging for terminally sterilised medical devices and sterilisation of health care productsCommission Implementing Decision (EU) 2021/610 of 14 April 2021 amending Implementing Decision (EU) 2020/437 as regards harmonised standards on medical vehicles and their equipment, anaesthetic and respiratory equipment, biological evaluation of medical devices, packaging for terminally sterilised medical devices, sterilisation of health care products, clinical investigation of medical devices for human subjects, non-active surgical implants, medical devices utilising animal tissues and their derivatives, electroacoustics and medical electrical equipmentCommission Implementing Decision (EU) 2021/611 of 14 April 2021 amending Implementing Decision (EU) 2020/438 as regards harmonised standards on biological evaluation of medical devices, packaging for terminally sterilised medical devices, sterilisation of health care products and clinical investigation of medical devices for human subjectsCommission Decision (EU, Euratom) 2021/625 of 14 April 2021 on the establishment of the primary dealer network and the definition of eligibility criteria for lead and co-lead mandates for syndicated transactions for the purposes of the borrowing activities by the Commission on behalf of the Union and of the European Atomic Energy CommunityCommission Implementing Decision (EU) 2021/626 of 14 April 2021 establishing the InvestEU Portal and setting out its technical specifications
Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.
What to look at next
Browse all EU Legal ActsEvery instrument by type and year, full text free to read section by sectionEuropean Union legislationEU Legal Acts by type and yearGrouped by instrument type and year of enactment, so you can find others of the same kindBrowse by type and yearEuropean Union: what this database coversWhich datasets are here, which official source they come from, and how current they areEuropean Union overview